Home
Issues
Aim & Scope
Open Access
Indexing
Why publish with us
Contact
Editorial Board
Instructions to Authors (PDF)
Manuscript Types
Manuscript Formatting
How to submit
Preprints
Authorship & COI
Principles of Transparency Checklist
Publication Ethics and Publication Malpractice Statement
CrossMark
Data Policies
REVIEW
Lung cancer screening trials: Review of literature
1
Pulmonary Department, Aristotle University of Thessaloniki, “G. Papanikolaou” Hospital, Exohi, Thessaloniki, Greece
Corresponding author
Dionisios Spyratos
Pulmonary Medicine Pulmonary Department, Aristotle University of Thessaloniki, Greece
Pulmonary Medicine Pulmonary Department, Aristotle University of Thessaloniki, Greece
Pneumon 2018;31(3):159-166
KEYWORDS
ABSTRACT
Lung cancer is considered one of the most common causes of morbidity and mortality globally. Survival depends mainly on clinical stage of the disease, histological type of lung cancer and patient’s performance status. Implementation of a screening program among high-risk subjects might increase overall survival by increasing detection of lung cancers in early stages. In general an ideal screening program should be highly sensitive and specific, based on simple and safe examinations, cost effective and easily implemented. Low-dose computed tomography (LDCT) is currently the only proposed screening method for lung cancer. Based on the results of the National Lung Screening Trial (NLST), which was conducted in the USA and proved a 20% reduction in lung cancer specific related mortality, U.S. Preventive Services Task Force proposed official guidelines since 2014. In Europe there are no lung cancer screening recommendations/guidelines as the final results of the NELSON trial are still pending. The aim of this paper is to review the most important published trials on lung cancer screening.
REFERENCES (54)
1.
Global Burden of Disease Cancer Collaboration: Fitzmaurice C, Dicker D, Pain A, et al. The Global Burden of Cancer 2013. JAMA Oncol 2015;1:505-27.
2.
World Health Organization. Cancer. Fact Sheet Number 297. http://www.who.int/mediacentre... Last updated February 2015. Date last accessed: February 10, 2015.
3.
Goldstraw P, Chansky K, Crowley J, et al. The IASLC Lung Cancer Staging Project: Proposals for Revision of the TNM Stage Groupings in the Forthcoming (Eighth) Edition of the TNM Classification for Lung Cancer. J Thorac Oncol 2016;11:39-51.
4.
American Society of Clinical Oncology (ASCO). Lung Cancer - Small Cell: Statistics. Approved by the Cancer. Net Editorial Board, 10/2016. Available at: http://www.cancer.net/cancer-t... updated: Aug 28, 2015, Last accessed: April 2, 2017
5.
Moyer V, U.S. Preventive Services Task Force. Screening for Lung Cancer: U.S. Preventive Services Task Force Recommendation Statement. Ann Intern Med 2014;160:330-8.
6.
Humphrey L, Deffebach M, Pappas M, et al. Screening for Lung Cancer: Systematic Review to Update the U.S. Preventive Services Task Force Recommendation. AHRQ Publication 2013;13-05188-EF-1.
7.
The Centers for Medicare & Medicaid Services (CMS). National Coverage Determination (NCD) for Screening for Lung Cancer with Low Dose Computed Tomography (LDCT). 2015-02-05.
8.
Black WC. Overdiagnosis: An underrecognized cause of confusion and harm in cancer screening. J Natl Cancer Inst 2000;92:1280-2.
9.
Wender R, Fontham E, Barrera E, et al. American Cancer Society Lung Cancer Screening Guidelines. CA Cancer J Clin 2013;63:106-17.
10.
Jaklitsch MT, Jacobson FL, Austin JH. The American Association for Thoracic Surgery guidelines for lung cancer screening using low-dose computed tomography scans for lung cancer survivors and other high-risk groups. Journal of Thoracic and Cardiovascular Surgery 2012;144:33-8.
11.
Smith RA, Andrews K, Brooks D, et al. Cancer screening in the United States, 2016: A review of current American Cancer Society guidelines and current issues in cancer screening. CA: A Cancer Journal for Clinicians 2016;66:96-114.
12.
Manser R, Lethaby A, Irving LB, et al. Screening for lung cancer (Review). Cochrane Database Syst Rev 2013;(6):CD001991.
13.
Marcus PM, Bergstralh EJ, Fagerstrom RM, et al. Lung cancer mortality in the Mayo Lung Project: impact of extended followup. J Natl Cancer Inst 2000;92:1308-16.
14.
Melamed MR, Flehinger BJ, Zaman MB, et al. Screening for early lung cancer. Results of the Memorial Sloan-Kettering study in New York. Chest 1984;86:44-53.
15.
Prorok PC, Andriole GL, Bresalier RS, et al. Design of the Prostate, Lung, Colorectal and Ovarian (PLCO) Cancer Screening Trial. Control Clin Trials 2000;21: 273S-309S.
16.
Oken MM, Hocking WG, Kvale PA, et al. Screening by chest radiograph and lung cancer mortality: the Prostate, Lung, Colorectal, and Ovarian (PLCO) randomized trial. JAMA 2011;306:1865-73.
17.
Aberle D, Adams A, Berg C, et al. Reduced Lung Cancer Mortality with Low-Dose Computed Tomographic Screening. N Engl J Med 2011;365:395-409.
18.
Kovalchik S, Tammemagi M, Berg C, et al. Targeting of Low Dose CT Screening according to the risk of lung cancer death. N Engl J Med 2013;369:245-54.
19.
Black W, Gareen I, Soneji S, et al. Cost- effectiveness of CT screening in the National Lung Screening Trial. N Engl J Med 2014;371:1793-802.
20.
Henschke CI, McCauley DI, Yankelevitz DF, et al. Early Lung Cancer Action Project: overall design and findings from baseline screening. Lancet 1999;354:99-105.
21.
Henschke CI, Naidich DP, Yankelevitz DF, et al. Early Lung Cancer Action Project: initial findings on repeat screenings. Cancer 2000;92:153-9.
22.
Flieder DB, Vazquez M, Carter D, et al. Pathologic findings of lung tumors diagnosed on baseline CT screening. Am J Surg Pathol 2006;30:606-13.
23.
International Early Lung Cancer Action Program Investigators; Henschke CI, Yankelevitz DF, Libby DM, et al. Survival of Patients with Stage I Lung Cancer Detected on CT Screening N Engl J Med 2006;355:1763-71.
24.
Infante M, Cavuto S, Lutman FR, et al. A randomized study of lung cancer screening with spiral computed tomography. Three year Results from the DANTE Trial. Am J Respir Crit Care Med 2009;180:445-53.
25.
Infante M, Cavuto S, Lutman FR, et al. Long-Term Follow-up Results of the DANTE Trial, a Randomized Study of Lung Cancer Screening with spiral computed tomography. Am J Resp Crit Care Med 2015;191:1166-75.
26.
Pedersen J, Ashraf H, Dirksen A, et al. The Danish randomized Lung-cancer CT Screening Trial-overall design and results of the prevalence round. J Thorac Oncol 2009;4:608-14.
27.
Saghir Z, Dirksen A, Ashraf H, et al. CT screening for lung cancer brings forward early disease. The randomised Danish Lung Cancer Screening Trial: status after five annual screening rounds with low-dose CT. Thorax 2012;67:296-301.
28.
Wille MM, Dirksen A, Ashraf H, et al. Results of the randomized danish lung cancer screening trial with focus on high-risk profiling. Am J Respir Crit Care Med 2016;193:542-51.
29.
Rasmussen JF, Siersma V, Pedersen JH, et al. Psychosocial consequences in the Danish randomised controlled lung cancer screening trial (DLCST). Lung Cancer. 2015;87:65-72.
30.
Ashraf H, Saghir Z, Dirksen A, et al. Smoking habits in the randomised Danish Lung Cancer Screening Trial with lowdose CT: final results after a 5-year screening program. Thorax 2014;69:574-9.
31.
Pastorino U, Rossi M, Rosato V, et al. Annual or biennial CT screening versus observation in heavy smokers: 5-year results of the MILD trial. Eur J Cancer Prev 2012;21:308-15.
32.
Sverzellati N, Silva M, Calareso G, et al. Low-dose computed tomography for lung cancer screening: comparison of performance between annual and biennial screen. Eur Radiol 2016;26:3821-9.
33.
Lopes Pegna A, Picozzi G, Falaschi F, et al. Four-year results of low-dose CT screening and nodule management in the ITALUNG trial. J Thorac Oncol 2013;8:866-75.
34.
Becker N, Motsch E, Gross ML, et al. Randomized study on early detection of lung cancer with MSCT in Germany: study design and results of the first screening round. J Cancer Res Clin Oncol 2012;138:1475-86.
35.
Becker N, Motsch E, Gross ML et al. Randomized Study on Early Detection of Lung Cancer with MSCT in Germany: Results of the First 3 Years of Follow-up after Randomization. J Thorac Oncol 2015;10:890-6.
36.
McRonald F, Yadegarfar G, Baldwin D, et al. The UK Lung Screen (UKLS): Demographic profile of first 88,897 approaches provides recommendations for population screening. Cancer Prev Res 2014;7:362-71.
37.
Field JK, Duffy SW, Baldwin DR, et al. UK Lung cancer RCT Pilot Screening Trial: Baseline findings from the screening arm provide evidence for the potential implementation of lung cancer screening. Thorax 2016;71:161-70.
38.
Raji O, Duffy S, Olorunshola M, et al. Predictive accurancy of the liverpool lung project risk model for stratifying patients for computed tomography screening for lung cancer: A case-control and cohort Validation Study. Ann Intern Med 2012;157:242-50.
39.
Baldwin D, Duffy S, Wald N, et al. UK Lung Screen (UKLS) nodule management protocol: modeling of a single screen randomised controlled trial of low-dose CT screening for lung cancer. Thorax 2011;66:308-13.
40.
Van Iersel C, De Koning H, Draisma G, et al. Risk-based selection from the general population in a screening trial: Selection criteria, recruitment and power fort the Dutch-Belgian randomized lung cancer multi-slice CT screening trial (NELSON). Int J Cancer 2006;120:868-74.
41.
Van Klaveren RJ, Oudkerk M, Propok M, et al. Management of lung nodules detected by volume CT scanning. N Engl J Med 2009;361:2221-9.
42.
Horeweg N, van der Aalst C, Thunnissen E, et al. Characteristics of lung cancers detected by computer tomography screening in the randomized NELSON trial. Am J Respir Crit Care Med 2013;187:848-54.
43.
Horeweg N, Scholten ET, De Jong PA, et al. Detection of lung cancer through low-dose CT screening (NELSON): a prespecified analysis of screening test performance and interval cancers. Lancet Oncol 2014;15:1342-50.
44.
Yousaf-Khan U, van der Aalst C, De Jong PA, et al. Final screening round of the NELSON lung cancer screening trial: the effect of a 2,5 year screening interval. Thorax 2017;72:48-56.
45.
Walter JE, Heuvelmans MA, De Jong PA, et al. Occurence and lung cancer probability of new solid nodules at incidence screening with low- dose CT: analysis of data from the randomised, controlled NELSON trial. Lancet Oncol 2016;17:907-16.
46.
Yousaf-Khan U, van der Aalst C, Horeweg N, et al. Baseline characteristics and mortality outcomes of control group participants and eligible non-responders in the NELSON lung cancer screening study. J Thorac Oncol. 2015;10: 747-53.
47.
Van der Aalst CM, Van den Bergh KA, Willemsen MC, et al. Lung cancer screening and smoking abstinence: 2 year follow-up data from the Dutch Belgian randomized controlled lung cancer screening trial. Thorax 2010;65:600-5.
48.
Van den Bergh KAM, Essink-Bot ML, Borsboom GJJM, et al. Long-term effects of lung cancer computed tomography screening on health-related quality of life: the NELSON trial. Eur Respir J 2011;38:154-61.
49.
Van den Bergh K, Essink-Bot ML, Borsboom G, et al. Short term health related quality of life consequences in a lung cancer CT screening trial (NELSON). Br J Cancer 2010;102:27-34.
50.
National Comprehensive Cancer Network Clinical Practice Guidelines in Oncology. Lung cancer screening. Version 2. 2016.
51.
Canadian Task Force on Preventive Health Care. Recommendations on screening for lung cancer. CMAJ 2016;188:425-32.
52.
Kauczor HU, Bonomo L, Gaga M, et al. ESR/ERS white paper on lung cancer screening. Eur Respir J 2015;46:28-39.
53.
Field JK, Devaraj A, Duffy SW, Baldwin DR. CT screening for lung cancer: Is the evidence strong enough? Lung Cancer 2016;91:29-35.
54.
Oudkerk M, Devaraj A, Vliegenthart R, et al. European position statement on lung cancer screening. Lancet Oncol. Elsevier Ltd; 2017;18:e754–66.
Share
RELATED ARTICLE
| eISSN: | 1791-4914 |
| ISSN: | 1105-848X |
We process personal data collected when visiting the website. The function of obtaining information about users and their behavior is carried out by voluntarily entered information in forms and saving cookies in end devices. Data, including cookies, are used to provide services, improve the user experience and to analyze the traffic in accordance with the Privacy policy. Data are also collected and processed by Google Analytics tool (more).
You can change cookies settings in your browser. Restricted use of cookies in the browser configuration may affect some functionalities of the website.
You can change cookies settings in your browser. Restricted use of cookies in the browser configuration may affect some functionalities of the website.
